View in EDS

Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.

Saved in:
Bibliographic Details
Title: Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.
Authors: Lopez JS; Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK., Harrington KJ; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust National Institute of Health Research Biomedical Research Centre, London, UK., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea., Lee KW; Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Postel-Vinay S; Institut Gustave Roussy, Villejuif, France., Thomas JS; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA., Lukashchuk N; Translational Medicine Early Oncology, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK., Willis SE; Cancer Biomarker Development, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK., Irurzun-Arana I; Clinical Pharmacology Quantitative Pharmacology, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK.; GSK, Madrid, Spain., Webb B; Early Oncology Statistics, Biometrics Oncology, Oncology R&D, AstraZeneca, Cambridge, UK., Nehra J; Late Oncology Development, GI Cancer and Strategy, Oncology R&D, AstraZeneca, Waltham, MA, USA., Lau A; UK - SM Bioscience Team, Oncology Targeted Discovery, Oncology R&D, AstraZeneca, Cambridge, UK., Loembé AB; Early Oncology Clinical, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Experimental Medicine Oncology department, Boehringer-Ingelheim, Ingelheim, Germany., Dean E; Early ICA Projects, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK., Krebs MG; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK. matthew.krebs@manchester.ac.uk.
Source: British journal of cancer [Br J Cancer] 2026 Jun; Vol. 134 (11), pp. 1568-1579. Date of Electronic Publication: 2026 Mar 31.
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study
Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41917211
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lopez+JS%22">Lopez JS</searchLink>; Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK.<br /><searchLink fieldCode="AU" term="%22Harrington+KJ%22">Harrington KJ</searchLink>; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust National Institute of Health Research Biomedical Research Centre, London, UK.<br /><searchLink fieldCode="AU" term="%22Im+SA%22">Im SA</searchLink>; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+KW%22">Lee KW</searchLink>; Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Postel-Vinay+S%22">Postel-Vinay S</searchLink>; Institut Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Thomas+JS%22">Thomas JS</searchLink>; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Lukashchuk+N%22">Lukashchuk N</searchLink>; Translational Medicine Early Oncology, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Willis+SE%22">Willis SE</searchLink>; Cancer Biomarker Development, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Irurzun-Arana+I%22">Irurzun-Arana I</searchLink>; Clinical Pharmacology Quantitative Pharmacology, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK.; GSK, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Webb+B%22">Webb B</searchLink>; Early Oncology Statistics, Biometrics Oncology, Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Nehra+J%22">Nehra J</searchLink>; Late Oncology Development, GI Cancer and Strategy, Oncology R&D, AstraZeneca, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Lau+A%22">Lau A</searchLink>; UK - SM Bioscience Team, Oncology Targeted Discovery, Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Loembé+AB%22">Loembé AB</searchLink>; Early Oncology Clinical, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Experimental Medicine Oncology department, Boehringer-Ingelheim, Ingelheim, Germany.<br /><searchLink fieldCode="AU" term="%22Dean+E%22">Dean E</searchLink>; Early ICA Projects, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Krebs+MG%22">Krebs MG</searchLink>; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK. matthew.krebs@manchester.ac.uk.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220370635%22">British journal of cancer</searchLink> [Br J Cancer] 2026 Jun; Vol. 134 (11), pp. 1568-1579. <i>Date of Electronic Publication: </i>2026 Mar 31.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group+on+behalf+of+Cancer+Research+UK%22">Nature Publishing Group on behalf of Cancer Research UK </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0370635 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-1827 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200070920%22">00070920 </searchLink><i>NLM ISO Abbreviation: </i>Br J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41917211
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41416-026-03408-y
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1568
    Titles:
      – TitleFull: Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lopez JS
      – PersonEntity:
          Name:
            NameFull: Harrington KJ
      – PersonEntity:
          Name:
            NameFull: Im SA
      – PersonEntity:
          Name:
            NameFull: Lee KW
      – PersonEntity:
          Name:
            NameFull: Postel-Vinay S
      – PersonEntity:
          Name:
            NameFull: Thomas JS
      – PersonEntity:
          Name:
            NameFull: Lukashchuk N
      – PersonEntity:
          Name:
            NameFull: Willis SE
      – PersonEntity:
          Name:
            NameFull: Irurzun-Arana I
      – PersonEntity:
          Name:
            NameFull: Webb B
      – PersonEntity:
          Name:
            NameFull: Nehra J
      – PersonEntity:
          Name:
            NameFull: Lau A
      – PersonEntity:
          Name:
            NameFull: Loembé AB
      – PersonEntity:
          Name:
            NameFull: Dean E
      – PersonEntity:
          Name:
            NameFull: Krebs MG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2026 Jun
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1532-1827
          Numbering:
            – Type: volume
              Value: 134
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: British journal of cancer
              Type: main
ResultId 1